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ABSTRACT
The increasing prevalence of chronic kidney disease (CKD) and
diabetes over the last decade has resulted in increasing numbers
of frail older patients with a combination of these conditions.
Current treatment guidelines may not necessarily be relevant
for such patients, who are mostly excluded from the trials upon
which these recommendations are based. There is a paucity of
data upon which to base the management of older patients with
CKD. Nearly all current guidelines recommend less-tight gly-
caemic control for the older population, citing the lack of pro-
ven medium-term beneﬁts and concerns about the high short-
term risk of hypoglycaemia. However, reports from large land-
mark trials have shown potential beneﬁts for both microvascu-
lar and macrovascular complications, though the relevance of
these ﬁndings to this speciﬁc population is uncertain. The trials
have also highlighted potential alternative explanations for the
hazards of intensive glycaemic control. These include depres-
sion, low endogenous insulin reserve, low body mass index and
side effects of the medication. Over the last few years, newer
classes of hypoglycaemic drugs with a lower risk of hypogly-
caemia have emerged. This article aims to present a balanced
view of advantages and disadvantages of intense glycaemic con-
trol in this group of patients, which we hope will help the
clinician and patient to come to an individualized management
approach.
Keywords: chronic kidney disease, frail, glycaemic control,
older
INTRODUCTION
Older individuals represent the fastest growing group of people
worldwide [1, 2]. Along with this, the prevalence of type 2 dia-
betes has also increased and has emerged as a major health
problem especially in older people [3]. Old age and diabetes are
the two most important causes of decline in renal function [4].
In older individuals with chronic kidney disease (CKD) and dia-
betes, the risk of frailty is considerable [5]. Frailty can hereby be
defined as a clinical syndrome in which three or more of the fol-
lowing criteria are present: unintentional weight loss (10 lbs in
the past year), self-reported exhaustion, weakness (grip
strength), slow walking speed and low physical activity [6]. A
major characteristic of the frailty diathesis is an increased sus-
ceptibility to functional decline, dependency and death with
relatively minor clinical or psychosocial misadventures.
As a consequence a distinct, highly vulnerable, population is
emerging—frail older patients with diabetes mellitus and CKD.
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Management of these patients is often complex and specific
evidence-based treatment guidelines are often lacking. A
European multidisciplinary initiative recently identified and pri-
oritized potential topics to be addressed for this population. This
joint initiative of the European Renal Association–European
Dialysis Transplant Association and the European Union
Geriatric Medicine Society prioritized the development of guid-
ance on interdisciplinary referral of older patients with CKD
Stage 3b–5 and listed ‘glycaemic control’ as a topic of interest [7].
Decisions about the optimal degree of glycaemic control in
frail older patients with diabetes and advanced kidney disease
are often difficult. It is uncertain whether strict glycaemic
control results in benefit or harm in this population, espe-
cially as clinical trials on glycaemic control have almost al-
ways excluded patients with advanced CKD and/or frailty [8].
Older age was not an exclusion criteria in most clinical trials,
but the mean age of included patients was lower than 65 years
old [9]. However, the ADVANCE trial was different in this
regard, with a mean age of 66 years [10]. Observational stud-
ies suggested that, in patients with diabetes and more than
75 years old, an HbA1c below 6.9% can be protective when
compared with the general population [11]. However, if CKD
is one of the comorbidities, then all-cause mortality can
increase in the diabetes group from 37% up to 333%, depend-
ent on the estimated glomerular filtration rate (eGFR) [11].
However, in patients over 75 years old with CKD
(eGFR<60 mL/min/1.73 m2) those with diabetes had higher
hazard ratios for death than controls (1.02–3.33, depending on
eGFR). Moreover, trials of strict glycaemic control using con-
ventional anti-diabetic medication in the general population
have failed to show any benefits on cardiovascular outcomes
and mortality, with only a small gain for the outcome of micro-
vascular disease. In addition, intensive glycaemic control did
not reduce the development of end-stage renal disease (ESRD)
or doubling of the serum creatinine [12]. Trials did, however,
reveal increased mortality related to hypoglycaemia [13–15].
This increased risk of hypoglycaemia would seem to outweigh
any possible benefit of stricter glycaemic control. There are
other considerations. In advanced CKD some medications may
accumulate, increasing the risk of adverse events and hypogly-
caemia [16]. The HbA1c values in people with advanced CKD
can be misleading, as low HbA1c values in this patient group
may overestimate the quality of glycaemic control [17–19].
Conversely, one should keep in mind that uraemia itself can en-
hance glycation independent of capillary glucose readings [20].
Finally, frailty and old age are associated with a wide range of
comorbidities, a variable degree of cognitive dysfunction and a
decreased life expectancy [6, 21]. The net effect of these factors
may be to tip the balance away from the potential for long-term
benefit towards the likelihood of short-term harm.
In this review, we aim to consider the translation of data
derived from randomized controlled trials in other populations to
assist clinicians in the management of glycaemic control in frail
older patients with diabetes and advanced CKD. There is a pau-
city of data related to glycaemic management and control of type
1 diabetes later in life. Data on management of type 2 diabetes
cannot be extrapolated to this category of patients. Therefore, this
current article only focuses on patients with type 2 diabetes.
WHAT ARE THE CURRENT
RECOMMENDATIONS?
Current targets for glycaemic control in older and frail
individuals
According to the American Diabetes Association (ADA)
and the European Association for the Study of Diabetes
(EASD) consensus recommendations for frail and older
adults, individuals with limited life expectancy (1 year or
less), should have less-stringent HbA1c goals (7.5–8.0% or
even slightly higher in certain patients) [22–24]. The angio-
tensin-converting-enzyme inhibitor (AACE/ACE) Diabetes
Guidelines reinforced the recommendation for less stringent
HbA1c goals (7–8%) in patients with a high risk of hypogly-
caemia, long-standing diabetes or limited life expectancy
[25]. The International Diabetes Federation (IDF) global
guideline recommendation is an HbA1c target >7% for peo-
ple with limited life expectancy [26]. The International
Association of Gerontology and Geriatrics, the European
Diabetes Working Party for Older People and the
International Task Force of Experts in Diabetes have set the
HbA1c target range to between 7.0% and 7.5% in older peo-
ple, though this might be even higher in cases of lack of func-
tional independence [27]. Similarly, the American Geriatric
Society recommends a target HbA1c for older people of
<8.0% [28]. The National Institute of Clinical Excellence
guideline suggests that the HbA1c target should be <7.5% for
people with type 2 diabetes treated with insulin or triple oral
medication [29].
For individuals with diabetes and advanced CKD, the
Kidney Disease Outcomes Quality Initiative reinforced the
ADA recommendations [16, 30]. However, the 2012 Kidney
Disease: Improving Global Outcomes (KDIGO) guidelines rec-
ommended an HbA1c target >7.0% in individuals with comor-
bidities or limited life expectancy and with high risk of
hypoglycaemia [31]. In the ADA/EASD position statement
there is no specific recommendation for patients with advanced
CKD, but for patients with a limited life expectancy or extensive
comorbid conditions an HbA1c between 7.5% and 8.0% or even
higher is advocated [22]. Finally, the IDF global guideline sug-
gested a target HbA1c of 7.0–7.5% or higher in the presence of
modifying factors such as vulnerability to hypoglycaemia or the
presence of comorbidities [26].
Nephrology guidelines
The recent European Renal Best Practice Guideline on man-
agement of patients with diabetes with advanced CKD (http://
www.european-renal-best-practice.org/content/erbp-official-
documents) recommended against tighter glycaemic control if
this results in severe hypoglycaemic episodes [32]. Vigilant at-
tempts to tighten glycaemic control were considered reasonable
only with the intention to lower HbA1c when values are>8.5%
[32]). Urinary incontinence with polyuria should alert the clin-
ician to check for hyperglycaemia. Only if there is no evidence
of hypoglycaemia and HbA1c is>7% should clinicians try to in-
tensify treatment, though careful consideration of age and
comorbidities is mandatory.
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Hence, all current guidelines agree that in older people, espe-
cially those with comorbidities such as advanced CKD, gly-
caemic control should be less stringent. It is noteworthy that
there are no hard data justifying either stringent or less stringent
glycaemic control in this patient group.
ARGUMENTS FAVOURING LESS-TIGHT
GLYCAEMIC CONTROL
Microvascular endpoints
Although the three landmark studies on intensive glycaemic
control in people with long-standing diabetes [Action to Control
Cardiovascular Risk in Diabetes (ACCORD), Action in Diabetes
and Vascular Disease (ADVANCE) and The Veterans Affairs
Diabetes Trial (VADT)] included very few cases with advanced
CKD, and even fewer frail older patients, these studies are the
main source of evidence from which we can extrapolate data to
frail older patients with advanced CKD. In these studies, micro-
vascular hard endpoints such as the development of ESRD or
doubling of the serum creatinine were not reduced by intensive
glycaemic control in the initial reports [13–15]. These findings
were further supported by a systematic review [12]. Although
hard endpoints were unimproved in the short term, slight im-
provements in some were evident at later follow-up [33].
Cardiovascular endpoints and mortality
With regard to cardiovascular disease, the studies failed to
demonstrate any benefit of intensive glucose control [13–15].
Moreover, the ACCORD study was prematurely stopped because
of an unexpected 22% increase in the mortality rate in the inten-
sive glycaemic control arm [13]. Similar data emerged from stud-
ies in older people as well as from observational studies in
patients with CKD [8, 34–37]. Although there may be some abso-
lute risk reductions in some surrogate vascular endpoints, more
intense glycaemic therapy as applied in these trials cannot be jus-
tified when balanced against the risk of an increase in overall
mortality [38]. Another finding that shouldmoderate the tempta-
tion to implement more strict glycaemic control in patients with
long-standing diabetes and comorbidities comes from a second-
ary analysis of the VADT trial. In this analysis, the only factors
associated with new cardiovascular events were the presence of
previous cardiovascular events and lower HbA1c concentrations
prior to the event [39]. This raises further concerns about the
safety of intensive glycaemic control in patients with previous
cardiovascular events or at risk of hypoglycaemia.
Cognitive impairment and depression
Cognitive impairment may represent an important outcome,
since it is common in individuals with advanced CKD, with
more than two-thirds of patients experiencing moderate to
advanced cognitive impairment [40]. Likewise, patients with
long-standing diabetes have a 1.5-fold increased risk of cognitive
impairment and 2- to 4-fold increased risk of dementia [41]. In
this regard, the results from the ACCORD and ADVANCE trials
were disappointing, failing to provide any clinical benefit on cog-
nitive function tests [14, 42]. These results do not support a strat-
egy of tighter glycaemic control in frail older patients.
Depression may also be considered an important outcome
since it is prevalent in individuals with diabetes, in advanced
CKD and in older patients [43–45]. Moreover, depression is
linked to mortality in patients with advanced CKD [46–48]. In
patients with diabetes, depression confers strong risk of cognitive
decline, cardiovascular events and mortality. Good glycaemic
control did not improve its course [13, 49, 50]. These relation-
ships are two-way since the burden of diabetes, CKD or frailty
may lead to depressive symptoms, which may also be an import-
ant obstacle to achieving good glycaemic control [51, 52].
Hypoglycaemia and other health problems related to
quality of life
The risk of severe hypoglycaemic events increases with age, gly-
caemic control, diabetes duration, progression of renal insuffi-
ciency and polypharmacy [53, 54]. Furthermore, hypoglycaemia
may be aggravated by poor adherence and autonomic nervous
dysfunction [55, 56]. In the VADT trial, hypoglycaemia was asso-
ciated with an increased risk of cardiovascular events across all
groups [39]. Hypoglycaemia increases the risk of falls [57–60] and
fractures, decreasing independence and quality of life [61–63].
In older patients with diabetes and advanced CKD, main-
taining independence and an acceptable quality of life may be
more important than targeting a stringent HbA1c level, with the
intention of improving cardiovascular outcomes or medium- to
long-term survival [64]. In these patients, quality of life is
strongly associated with the burden of complex symptoms such
as pain, pruritus, restless legs, nausea and fatigue. Alleviating
these symptoms by treating anaemia or uraemia may be more
effective in improving quality of life than strict glycaemic con-
trol [65]. Lack of independence, as well as polypharmacy, may
have a great impact on quality of life [66, 67] (Figure 1).
FIGURE 1: Factors to consider in the decision-making with regard to relaxed or intensive glycaemic control.
G l y c a e m i c c o n t r o l i n o l d e r p a t i e n t s w i t h a d v a n c e d C K D 593
||
||
||
||
||
||
||
||
||
||
||
||
||
||
||
||
||
||
||
||
||
||
||
||
||
||
||
||
||
||
||
||
||
||
||
||
||
||
||
||
||
||
||
||
||
||
||
||
||
||
||
||
||
||
||
||
||
||
||
||
||
||
||
||
||
||
||
||
||
||
||
||
||
||
||
||
||
||
||
||
||
||
||
||
||
||
|
ARGUMENTS FAVOURING TIGHTER
GLYCAEMIC CONTROL
The type of medication prescribed
When ACCORD, ADVANCE and VADT were performed,
the only available glycaemia-lowering drugs were metformin,
sulfonylureas, thiazolidinediones and insulins. Hence, in these
studies many patients had regimes including sulfonylureas (50–
71% of the patients) and/or insulin (40–87%) [68]. Both classes
of agents exert their action independently of the blood glucose
concentrations, having a continuous hypoglycaemic action and
accordingly, a high risk for hypoglycaemia [53, 69]. More re-
cently, the importance of postprandial glycaemic control in
achieving better glycaemic control has been highlighted [70].
Older trials did not have the tools to adequately address both
fasting and postprandial hyperglycaemia without conferring a
high risk of hypoglycaemia. Now new classes of drugs have
emerged that can safely address postprandial glycaemia. Some
of these can be used in patients with advanced CKD [71]. These
new drugs have shown acceptable safety profiles with respect to
hypoglycaemia even in older patients [72]. Ongoing trials will
determine whether use of these drugs confers any clinical
benefit.
Microvascular endpoints
More intensive glycaemic control than currently recom-
mended in older people with long diabetes duration also gains
some support from signals of clinical benefit observed in the
landmark trials. In the ADVANCE trial, the composite renal
complications were reduced by 9%, mainly due to a 31% reduc-
tion in new onset macro-albuminuria, without increased mor-
tality [73]. A later report from the same population showed a
65% reduction in the risk of progression to ESRD associated
with intensive glycaemic control [33]. The absolute risk reduc-
tion was maximal in advanced CKD compared with the earlier
stages [74]. A number of other defined renal outcomes were
also reduced in ACCORD and VADT [15, 75]. The data also
suggest that, in these respects, patients with type 2 diabetes and
advanced CKD do not differ significantly from patients with
type 2 diabetes without CKD.
Macrovascular endpoints
Although the initial reports of the VADT trial were negative,
10-year follow-up data demonstrated a 17% reduction in major
cardiovascular events [76], although no reduction in overall
mortality. The study population had a duration of diabetes of
>10 years and a baseline HbA1c of 9.5%. There were improve-
ments in macrovascular outcomes after a period of intensive
treatment for 5.6 years. The best achieved mean HbA1c level
was 6.9%, although this was followed by a small but persistent
decline in the degree of glycaemic control [76]. It can be debated
whether frail older people have sufficient life expectancy to
benefit from these relatively small improvements.
Cognitive impairment and depression
Several studies have shown an association between higher
glucose concentrations and worse cognitive performance, in
both cross-sectional and retrospective analyses [77, 78]. In lon-
gitudinal observational studies, having diabetes seemed to en-
hance the effects of normal ageing by a factor of 1.5–2 over a
period of 5 years [79–82]. Whether this effect is due to sustained
hyperglycaemia or episodic hypoglycaemia is not clear. The
beneficial effect of glycaemic control on cognitive function is
supported by a randomized controlled trial that demonstrated a
reduction in the rate of global cognitive decline after 5 years of
improved glycaemic control [83, 84]. However, these studies
focused primarily on the impact of telemedicine on HbA1c con-
trol, and did not separately assess the role of tighter glycaemic
control.
Time required to experience potential benefits
Even if there were some benefits of good glycaemic control,
one might argue that many frail older people with advanced
CKD may not survive long enough to experience the potential
benefits of good glycaemic control. It appears that the benefits
on microvascular disease may only emerge after 5 years or so in
patients with long-standing diabetes and high cardiovascular
risk, and that macrovascular benefits may need even longer fol-
low-up [14, 15, 33, 75, 76, 85, 86]. Similar studies in older pa-
tients have shown that the time needed to observe benefits from
tight glycaemic control in terms of microvascular complications
was around 8 years [69]. In the diabetes population in general,
there is a strong case for multiple and comprehensive interven-
tions in patients with multiple risk factors [87]. The extent to
which this applies to those who are old, frail and with advanced
CKD needs to be carefully considered on an individual basis.
The new ‘cardiovascular’ glucose-lowering agents
Recent published data of randomized glucose-lowering
agents showed cardiovascular and mortality benefits (e.g.
EMPAREG Outcome trial, LEADER trial, SUSTAIN-6 trial) or
kidney benefits (e.g. EMPAREG [88], ADVANCE-ON [86]) in
patients with long-standing diabetes and high cardiovascular
risk treated to achieve an HbA1c of <7%. Whether the results
can be generalized to older, frailer patients with advanced CKD
is difficult to assess.
LEADER was an international, multicentred, randomized,
double-blind, placebo-controlled trial comparing the safety and
efficacy of the long-acting Glucagon-like peptide 1 receptor
(GLP-1) agonist, liraglutide versus placebo in over 9340 people
with type 2 diabetes mellitus and high cardiovascular risk [89].
More than 80% of participants had a history of previous cardio-
vascular disease. There was a reduction in rates of major cardio-
vascular events in patients randomized to liraglutide (13.0%
versus 14.9%, respectively). The number needed to treat (NNT)
to prevent one event over the 3-year period was 66 for major
cardiovascular events and 98 for death from any cause.
Liraglutide also reduced HbA1c, body weight and incidence of
hypoglycaemia. Its safety profile was similar to that seen in pre-
vious trials, with gastrointestinal adverse events and increases in
heart rate being the most common. Only one-quarter of those
randomized had an eGFR <60 mL/min/1.73 m2. Mean age
(6 standard deviation) was 64.46 7.2 years.
SUSTAIN-6 was a multicentred, international, randomized,
double-blind, placebo-controlled trial, investigating the long-
594 N.M. Panduru et al.
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term effects of semaglutide (0.5 and 1.0mg), a long-acting GLP-
1 receptor agonist, administered once weekly in adults with type
2 diabetes at high risk of cardiovascular events. In total, 3297
patients aged over 50 years (mean age 64.66 7.4 years) with
type 2 diabetes and an HbA1c of 7% or more were randomized
[90]. Of these, 2735 had established cardiovascular disease,
CKD or both, but actual eGFRs were not provided; the remain-
der were aged at least 60 years with at least one cardiovascular
risk factor. Mean duration of diabetes was 13.9 years and mean
HbA1c was 8.7%. Patients treated with semaglutide had a 26%
lower risk of the primary composite outcome of cardiovascular
death, non-fatal myocardial infarction or non-fatal stroke over
2 years compared with those receiving placebo. The NNT to
prevent one event of the primary outcome over 2 years was 45.
The IDF recommends a restricted use of GLP-1 in the older
population with or without CKD due to lack of long-term out-
come and safety data in this specific population [91]. However,
the recommendations are based on the information available in
2013, when the results of the recent trials mentioned above were
not yet available. Their low potential for hypoglycaemia and
availability for use as once a day or once a week make them
seem attractive for use in older people. However, gastrointes-
tinal side effects such as nausea and vomiting are common,
which may not be appropriate for frail older people in whom
weight loss and anorexia can be detrimental.
The multicentre Empagliflozin, Cardiovascular Outcomes
and Mortality in Type 2 Diabetes trial (EMPA-REG
OUTCOME) randomized 7020 patients to daily empagliflozin
(10 or 25mg), a sodium–glucose cotransporter 2 inhibitor
(SGLT2-I) or placebo [88]. At 3.1 years of follow-up, empagli-
flozin was associated with a reduction of a composite endpoint
consisting of cardiovascular mortality, non-fatal myocardial
infarction, or non-fatal stroke (10.5% versus 12.1%; P¼ 0.04),
as well as a reduction in all-cause mortality (5.7% versus 8.3%;
P< 0.001; NNT 38) and cardiovascular mortality (3.7% versus
5.9%; P< 0.001; NNT 45). Mean age of the included patients
was 63.16 8.6 years. Patients with eGFR<30 mL/min/1.73 m2
were excluded from the trial, but around one-quarter of
randomized patients had an eGFR between 30 and 60 mL/min/
1.73 m2. Although SGLT2 inhibitors have the advantage of low
risk of hypoglycaemia and weight loss, their renal mode of ac-
tion results in reduced efficacy in the presence of renal insuffi-
ciency. In addition, they can induce hypovolaemia and postural
hypotension, further enhancing the risk of falls in an older
population. They are also associated with an increased risk of
genital and urinary tract infections. Taking all these into consid-
eration, it can be stated that SGLT2 inhibitors are not really
suitable drugs in older and frail patients with advanced CKD.
CONCLUSIONS
It is clear that intensive glycaemic control is not appropriate for
many or even most frail older people with advanced CKD.
Some subgroups may benefit from more intensive glycaemic
control, such as those with a life expectancy of>5 years. In add-
ition, if more intensive treatment is prescribed, it should be im-
plemented with a medication that has a good safety profile and
lower risk of hypoglycaemia (Table 1).
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